The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback